Evidence map›Paper›PMID 34526506›Full record

ArticleNature communications2021

A prostate-specific membrane antigen activated molecular rotor for real-time fluorescence imaging.

Jingming Zhang, Anastasia Rakhimbekova, Xiaojiang Duan, Qingqing Yin, Catherine A Foss, Yan Fan, Yangyang Xu, Xuesong Li, Xuekang Cai, Zsofia Kutil and 7 more

Abstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. The [18F] F-PSMA Probe: Chemical Perspectives.Current medicinal chemistry · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jingming Zhang *Department of Nuclear Medicine, Peking University First Hospital, 100034, Beijing, China.
Anastasia Rakhimbekova *Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 25250, Vestec, Czech Republic.
Xiaojiang Duan *Department of Nuclear Medicine, Peking University First Hospital, 100034, Beijing, China.
Qingqing YinState Key Laboratory of Natural and Biomimetic Drugs, Peking University, 100191, Beijing, China.
Catherine A FossRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Yan FanDepartment of Nuclear Medicine, Peking University First Hospital, 100034, Beijing, China.
Yangyang XuDepartment of Urology, Peking University First Hospital, 100034, Beijing, China.
Xuesong LiDepartment of Urology, Peking University First Hospital, 100034, Beijing, China.
Xuekang CaiDepartment of Nuclear Medicine, Peking University First Hospital, 100034, Beijing, China.
Zsofia KutilInstitute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 25250, Vestec, Czech Republic.
Pengyuan WangDepartment of General Surgery, Peking University First Hospital, 100034, Beijing, China.
Zhi YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, 100142, Beijing, China.
Ning ZhangTranslational Cancer Research Center, Peking University First Hospital, 100034, Beijing, China.ORCID 0000-0001-7182-0100
Martin G PomperRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Yiguang WangState Key Laboratory of Natural and Biomimetic Drugs, Peking University, 100191, Beijing, China. yiguang.wang@pku.edu.cn.ORCID 0000-0002-1676-4211
Cyril BařinkaInstitute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 25250, Vestec, Czech Republic. cyril.barinka@ibt.cas.cz.ORCID 0000-0003-2751-3060
Xing YangDepartment of Nuclear Medicine, Peking University First Hospital, 100034, Beijing, China. yangxing2017@bjmu.edu.cn.ORCID 0000-0001-5186-4990

Funding

PSMA-based Cancer Imaging AgentsR01CA134675 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI POMPER, MARTIN G · 2009 to 2025
$6.2M
Austrian Science Fund FWF DOC 130NCI NIH HHS R01 CA134675
6 · The paper itself

Abstract

Surgery is an efficient way to treat localized prostate cancer (PCa), however, it is challenging to demarcate rapidly and accurately the tumor boundary intraoperatively, as existing tumor detection methods are seldom performed in real-time. To overcome those limitations, we develop a fluorescent molecular rotor that specifically targets the prostate-specific membrane antigen (PSMA), an established marker for PCa. The probes have picomolar affinity (IC

Indexed as

AnimalsAntigens, SurfaceBinding SitesCell Line, TumorEndocytosisGlutamate Carboxypeptidase IIHumansMaleMiceMice, Inbred BALB CMice, NudeModels, MolecularMolecular ProbesOptical ImagingPC-3 CellsProstatic NeoplasmsAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIMolecular Probes

Identifiers

PMID34526506
PMCPMC8443597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.